Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
September 10 2020 - 9:00AM
Business Wire
Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK)
affiliate and exclusively-licensed distributor of NantKwest’s
proprietary off-the-shelf NK-92® natural killer cells in certain
fields, announces the licensing of its next-generation natural
killer-based bioanalytical testing solution to Fresenius Kabi
SwissBioSim GmbH (“Fresenius”), a Switzerland-based global
healthcare company focusing on autoimmune diseases and
oncology.
Brink Biologics offers a variety of GLP and research-grade
NK-92® based cell lines as part of its Neukopanel® portfolio of
products for laboratory testing applications. Neukopanel® includes
discovery, translational and developmental research as well as
commercial lot release testing of clinical products. Brink products
are utilized widely by large pharmaceuticals and biotechnology
companies to support products ranging from anti-viral and dendritic
cell vaccines, therapeutic monoclonal antibodies and biosimilars,
bi- and tri-specific fusion proteins, cytokines, natural killer
cell checkpoint inhibitors and other biologic products.
The laboratory use of live natural killer cell cultures for
functional assays, such as antibody dependent cellular
cytotoxicity, antibody-dependent cell-mediated viral inhibition and
cytokine release assays, most closely approximates what one would
actually see in target patient populations. Of all the sources of
natural killer cells, Brink’s NK-92® natural killer cells are
considered to be the gold standard when it comes to providing
greater assay consistency and reproducibility, testing scalability,
and reduced labor time and costs for laboratory scientists and
technicians. These features give a competitive edge to companies
licensed to use Brink’s NK-92® products.
Fresenius has joined the growing list of leading biotechnology
companies that are using Brink’s NK-92® cell line for laboratory
based bioanalytical testing.
“Since our proprietary NK-92® cell line provides unique
advantages to commercial and academic researchers as well as
commercial manufacturers, we are committed to making our
bioanalytical testing solutions widely available to the public
through standard licensing agreements using market-driven terms and
conditions,” said Barry Simon, M.D., CEO of Brink Biologics and
President of NantKwest. “A growing number of commercial large
pharma, biotech and device companies are joining scores of academic
researchers who have accessed our NK-92 based cell lines to
facilitate their internal activities. Our affiliate, NantKwest, has
manufactured more than three trillion GMP-grade NK-92® cells and
hundreds of doses of clinical product have been administered to
patients in clinical trials since 2017. This positions NK-92® well
to grow as a leading functional cell-based testing platform to
complement its role as a leading immunotherapy platform, currently
under development. We are pleased to make our testing solution
available to Fresenius to facilitate their research and development
endeavors.”
About Brink Biologics
Brink Biologics, Inc. is a NantKwest, Inc. affiliated
next-generation bioanalytical testing solutions company located in
the Torrey Pines Biotechnology Science Park in San Diego, Calif.
NK-92® cell lines are natural killer cell lines originating from a
singular source, established in stable cultures under GLP & GMP
conditions and further modified and assembled into distinct panels
of cell-lines, suitable for a range of laboratory testing
applications. These Neukopanel® cell lines include both CD16-free
and CD16 expressing NK-92® cells, providing for the first time the
means to establish a consistent, robust, and reliable assay for
assessment of functional activity of a wide range of biologic
agents. NEUKOPANEL is a trademark of Brink Biologics, Inc. For
additional information and licensing inquiries, please visit
www.brinkbiologics.com.
About NantKwest
NantKwest (NASDAQ: NK) is an innovative, clinical-stage
immunotherapy company focused on harnessing the power of the innate
immune system to treat cancer and virally-induced infectious
diseases. NantKwest is the leading producer of clinical dose forms
of off-the-shelf natural killer cell therapies. The activated
natural killer cell platform is designed to destroy cancer and
virally-infected cells. The safety of these optimized, activated
natural killer cells—as well as their activity against a broad
range of cancers—has been tested in phase I clinical trials in
Canada and Europe, as well as in multiple phase I and II clinical
trials in the United States. By leveraging an integrated and
extensive genomics and transcriptomics discovery and development
engine, together with a pipeline of multiple, clinical-stage,
immuno-oncology programs, NantKwest seeks to transform medicine by
delivering living drugs-in-a-bag and bringing novel natural killer
cell-based therapies to routine clinical care. NantKwest is a
member of the NantWorks ecosystem of companies. For more
information, please visit www.nantkwest.com
NK-92® and haNK® are registered trademarks of NantKwest,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying that NantKwest will be successful in improving the
treatment of cancer or other critical illnesses, including
COVID-19. Risks and uncertainties related to these endeavors
include, but are not limited to, obtaining FDA approval of
NantKwest’s natural killer cells as well as other therapeutics and
manufacturing challenges.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are
described in detail in its Securities and Exchange Commission
filings, including in NantKwest’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2020. These forward-looking statements
speak only as of the date hereof, and we disclaim any obligation to
update these statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200910005382/en/
Jen Hodson NANT Jen@nant.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024